<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23559">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02145013</url>
  </required_header>
  <id_info>
    <org_study_id>LIM Chetana</org_study_id>
    <nct_id>NCT02145013</nct_id>
  </id_info>
  <brief_title>Assessment of Portal Hypertension Before Liver Resection in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Assessment of Portal Hypertension Before Liver Resection in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henri Mondor University Hospital</source>
  <oversight_info>
    <authority>France: haute autorit√© de sante</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the BCLC guidelines, surgical resection of hepatocellular carcinoma
      complicating cirrhosis is restricted to patients with preserved liver function.

      However, the surgical indications for hepatocellular carcinoma  with portal hypertension
      remain controversial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In-hospital or 90-day mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>90 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>overall and liver-related complications including liver failure, ascites, biliary fistula, bleeding, pulmonary complications, and renal complications.
Grading system according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Liver Cancers</condition>
  <arm_group>
    <arm_group_label>hepatocellular carcinoma</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with hepatocellular carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with hepatocellular carcinoma who undergo surgical resection (intention to
             treat analysis)

        Exclusion Criteria:

          -  extra-hepatic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniel Azoulay, MD, PhD</last_name>
    <email>daniel.azoulay@hmn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henri Mondor University Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chetana Lim</last_name>
      <email>chetana.lim@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008 Jun;134(7):1908-16. doi: 10.1053/j.gastro.2008.02.091. Epub 2008 Mar 8. PubMed</citation>
    <PMID>18549877</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henri Mondor University Hospital</investigator_affiliation>
    <investigator_full_name>Chetana LIM</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>portal hypertension, cirrhosis, hepatocellular carcinoma, surgical treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
